Jushi Holdings (JUSHF) Income from Non-Controlling Interests (2021)
Jushi Holdings' (JUSHF) quarterly Income from Non-Controlling Interests came in at -$2.3 million in Q4 2021, down 3682.26% on a QoQ basis from -$62000.0 in Q3 2021.
Jushi Holdings (JUSHF) Income from Non-Controlling Interests (2021) Analysis & Trends
Jushi Holdings (JUSHF) has 1 years of Income from Non-Controlling Interests data on file, last reported at -$2.3 million in Q4 2021.
- On a quarterly basis, Income from Non-Controlling Interests changed N/A year-over-year to -$2.3 million in Q4 2021; TTM through Sep 2022 was -$2.3 million, a N/A change from a year earlier, with the FY2021 full-year figure at -$2.8 million, down 45.28% from the prior year.
- Income from Non-Controlling Interests for Q4 2021 stood at -$2.3 million, down from -$62000.0 in the prior quarter.
- Over the last five years, Income from Non-Controlling Interests for JUSHF reached as high as -$62000.0 in Q3 2021 and fell as low as -$2.3 million in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | - |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | 395,346.10 |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | - |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | -12.70 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | - |
| 10 | Jushi Holdings | 81.25 Mn | 41.54 Mn | 29.88 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | -2.35 Mn |
| Sep 30, 2021 | -62,000.00 |
| Jun 30, 2021 | -190,000.00 |